1,700 Shares in Humana Inc. (NYSE:HUM) Bought by Washington Capital Management Inc.

Washington Capital Management Inc. acquired a new stake in Humana Inc. (NYSE:HUM) during the fourth quarter, HoldingsChannel reports. The fund acquired 1,700 shares of the insurance provider’s stock, valued at approximately $431,000.

Several other institutional investors also recently bought and sold shares of the company. Swedbank AB boosted its holdings in shares of Humana by 6.4% in the fourth quarter. Swedbank AB now owns 112,790 shares of the insurance provider’s stock valued at $28,616,000 after acquiring an additional 6,814 shares in the last quarter. Forsta AP Fonden lifted its position in Humana by 2.0% in the fourth quarter. Forsta AP Fonden now owns 25,200 shares of the insurance provider’s stock valued at $6,393,000 after purchasing an additional 500 shares during the period. Asset Dedication LLC boosted its holdings in Humana by 73.5% in the 4th quarter. Asset Dedication LLC now owns 800 shares of the insurance provider’s stock valued at $203,000 after purchasing an additional 339 shares in the last quarter. Matrix Asset Advisors Inc. NY acquired a new position in Humana during the 4th quarter worth approximately $1,674,000. Finally, Revolve Wealth Partners LLC purchased a new position in shares of Humana during the 4th quarter worth approximately $202,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.32% of the company’s stock.

Humana Price Performance

Humana stock opened at $294.18 on Thursday. The firm’s 50-day moving average is $275.44 and its two-hundred day moving average is $303.14. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $35.42 billion, a P/E ratio of 26.06, a P/E/G ratio of 2.15 and a beta of 0.55. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Equities analysts predict that Humana Inc. will post 16.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HUM. Piper Sandler lifted their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Stephens reiterated an “equal weight” rating and issued a $250.00 price target on shares of Humana in a report on Wednesday, October 9th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Finally, Oppenheimer dropped their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.